Acasti Pharma Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.acastipharma.com

Market Cap $51.78M
PE -4
Debt $NaN
Cash $15.16M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-11.61M
EBIT	-$13.93M
ROE	-21%
ROA	-21%
Equity	$56.13M
Growth Stability	1
PE	-4.46
PB	0.92
Price/Cash	0.29
Equity CAGR	56%
Earnings Growth YoY	5%
Earnings Growth QoQ	31%

Equity CAGR 5Y	38%
Equity CAGR 3Y	-24%
Market Cap	$51.78M
Assets	$65.35M
Cash	$15.16M
Shares Outstanding	11.51M
Working Capital	13.39M
Current Ratio	6.01
Shares Growth 3y	30%
Equity Growth QoQ	-5%
Equity Growth YoY	-16%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

SEC Filings

Direct access to Acasti Pharma Inc. (GRCE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does Acasti Pharma Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Acasti Pharma Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Acasti Pharma Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Acasti Pharma Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	02/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	-	-	-	-	-	-10K%	-10%	-	-	-
ROA	-	-	-	-	-107%	-26%	-8%	-66%	-18%	-21%
ROE	-	-	-	-	-196%	-35%	-9%	-62%	-21%	-21%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	02/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	0.12	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	02/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	51K%	-	-	-
Earnings YoY growth	-	78%	91%	140%	-51%	-23%	-50%	332%	-70%	-
Equity YoY growth	-	-	-	54%	18%	328%	95%	-37%	-9%	38%
FCF YoY growth	-	-	-	-	-	-38%	20%	-8%	-	-